Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | FPR2 | P25090 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | MME | P08473 | 2/20 | 0.38 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4134081 | 0.72 | EPHX1 (0.44) | — | |
| SCHEMBL25363264 | 0.72 | SIGMAR1 (0.31) | L3MBTL1NPC1RAB9AMEN1KMT2A | |
| SCHEMBL29523561 | 0.72 | SIGMAR1 (0.31) | L3MBTL1NPC1RAB9AMEN1KMT2A | |
| SCHEMBL25363267 | 0.72 | SIGMAR1 (0.31) | L3MBTL1NPC1RAB9AMEN1KMT2A | |
| SCHEMBL25363271 | 0.72 | SIGMAR1 (0.31) | L3MBTL1NPC1RAB9AMEN1KMT2A | |
| SCHEMBL18921065 | 0.70 | S1PR4 (0.43) | ALDH1A1HTTNCOA1SMN1; SMN2NCOA3 | |
| SCHEMBL1901572 | 0.69 | FPR2 (0.52) | L3MBTL1FPR2NPC1RAB9AMEN1 | |
| SCHEMBL3511843 | 0.69 | ALDH1A1 (0.48) | ALDH1A1SMN1; SMN2MMECTRB1 | |
| SCHEMBL3506437 | 0.69 | ALDH1A1 (0.48) | ALDH1A1SMN1; SMN2MMECTRB1 | |
| SCHEMBL3506435 | 0.69 | ALDH1A1 (0.48) | ALDH1A1SMN1; SMN2MMECTRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8466295-B2 | Thiophene derivatives as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-06-18 | — | — | US | disclosed |
| US-20090253766-A1 | THIOPHENE DERIVATIVES AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2009-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253766-A1 | THIOPHENE DERIVATIVES AS FACTOR XIA INHIBITORS | TFPI, F12, F11 | ALDH1A1 2061/4885HTT 3888/4885NCOA1 1269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.